Noopept
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Noopept is mainly a study-session and verbal-fluency nootropic: users reach for it when the bottleneck is absorbing dense material, retaining what they read, or turning thoughts into clearer speech.
Generally well-tolerated at 10–30 mg/day oral; headache (choline-depletion driven), irritability, and sleep disruption are the most common adverse effects and are dose- and timing-dependent.
Noopept is mainly a study-session and verbal-fluency nootropic: users reach for it when the bottleneck is absorbing dense material, retaining what they read, or turning thoughts into clearer speech. Its stronger neuroprotection case comes from Russian impaired-population use and preclinical mechanisms, not from large healthy-adult trials.
The ordinary failure modes are practical rather than organ-toxic: choline-depletion headache, irritability, sleep disruption after late dosing, tolerance with daily use, and non-response from phenotype or sourcing. Blood-pressure elevation is a watch item in community reports, but the signal is uncertain rather than a proven high-frequency clinical risk.
Low-dose oral cognition support with a distinctive verbal-clarity / information-absorption signature when it works. The value is best for users who can source tested product, respect morning-only dosing, and treat the Russian clinical record as impaired-population evidence rather than proof of broad healthy-adult enhancement.
Strongly bimodal. The positive camp reports unusually recognizable verbal fluency, fewer rereads of dense material, calmer mood tone, and better memory consolidation; the negative camp reports no obvious acute effect at standard doses. That split makes sourcing and self-tracking more important than the low milligram dose suggests.
Do not combine Noopept with other strongly cholinergic compounds without titrating choline supplementation carefully — over-cholinergic headache is the most frequently reported dose-limiting event.
Intro
Noopept (GVS-111; N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic dipeptide-derived small molecule developed at the Zakusov Institute of Pharmacology in Moscow in the 1990s.
It is structurally related to the piracetam-glycine dipeptide scaffold but is not a racetam: its N-phenylacetyl group and C-terminal ethyl ester modification make it a small molecule by standard chemical classification, not a peptide, despite its origins in peptide chemistry. These same modifications account for its oral bioavailability — a property absent in true peptides like Semax or Cerebrolysin.
The compound is often described as 'roughly 1,000 times more potent by weight than piracetam.' This comparison reflects dose equivalence, not efficacy superiority. The 1,000× figure means Noopept is pharmacologically active at doses approximately 1,000 times lower by weight than those required for piracetam to produce equivalent effects — it does not mean Noopept produces 1,000 times greater cognitive improvement. No head-to-head human efficacy comparison with piracetam exists.
Noopept is approved as a pharmaceutical drug in Russia where it is prescribed at 10 mg twice daily for cognitive impairments of cerebrovascular and traumatic origin. It is in a regulatory grey area in the United States and most of Western Europe, where it is sold as a research compound or supplement. No large-scale, placebo-controlled clinical trial of Noopept has been published in English-language peer-reviewed journals — this evidence gap, not a safety finding, is the direct reason for Western regulatory non-acceptance.
Community use is dominated by the study-enhancement context: Noopept is used acutely before cognitive sessions requiring information absorption, comprehension of dense material, and verbal fluency. It is classified as an 'information absorption' compound — distinct in function from dihexa (recollection and stimulatory) or bromantane (interconnection of existing information). These are complementary, not interchangeable, cognitive mechanisms.
Observed Effects
The most consistently reported acute effects are information retention and comprehension speed — users describe reading fewer passes of dense technical material to achieve the same level of understanding, and find comprehension of complex studies significantly improved. Verbal fluency and articulation are also frequently highlighted: many users report improved ability to express ideas clearly in real-time, find words more readily, and communicate with less latency between thought and speech. This verbal fluency effect may be the most reliably detected acute outcome across community accounts.
Focus and sustained attention for cognitively demanding tasks are reported at standard doses. Mental arithmetic and grasping difficult concepts are described as easier. Working memory improvement tends to manifest over the subacute phase (1–4 weeks), with some evidence from animal studies that chronic dosing produces greater neurotrophic gains than acute dosing. A subset of users also reports pattern recognition improvement and visual sharpness — enhanced colour saturation and sensory clarity, particularly at onset.
A mild anxiolytic effect — described as calm, reduced mental chatter, or reduced inner monologue rather than sedation — is reported at standard doses. A distinct and more profound mood normalisation experience has been reported by a subset of users during the first days of a cycle: persistent negative thought cycling stops, a sense of weight is lifted, emotional tone shifts to peaceful and serene rather than euphoric. This experience is not universal and does not appear dose-dependent within standard ranges.
Emotional sensitivity reduction — a dampening of emotional reactivity distinct from the anxiolytic calm — is reported by some users. At high doses (100 mg+), a delayed profound calm and serene mood state has been reported, emerging the morning after a large dose rather than immediately.
A meaningful proportion of users report no perceptible acute effect at standard doses — no boost in energy, focus, or mood. Non-response may be phenotypic, dose-related, or sourcing-related (purity of gray-market powder). Some non-responders at standard doses noted benefit only when combining Noopept with complementary nootropics in a stack.
Field Reports
Verbal fluency and articulation are the most reliably and distinctively reported acute effects across community experience logs.
The ability to express ideas clearly, find words more easily, and communicate with less latency between thought and speech is described by experienced nootropic users as Noopept's most consistent and recognisable signature. This is distinct from a general stimulant effect and specific enough that users can reliably identify it as Noopept's contribution in a stack.
Information retention and comprehension speed are the second most consistently reported effect. Dense technical reading — scientific papers, legal documents, complex study material — requires fewer passes when on Noopept. The operational measure most commonly used is 'how many times I have to re-read a paragraph to understand it.' Users describe comprehension as deeper and re-reads as significantly fewer.
A profound mood normalisation experience is reported by a meaningful subset of users, typically during the first days of a new cycle. Persistent negative thought cycling stops. A sense of weight is lifted. Emotional tone shifts from baseline dysphoria or low-grade anxiety to calm, peaceful, and serene — not euphoric. This experience is more commonly described by users who have some history of mood dysregulation or stress-driven cognitive impairment. It is not universal. The proposed mechanism — hypothalamic BDNF upregulation after chronic dosing — is consistent with this temporal pattern (emerging over days rather than hours).
Sensory enhancement is occasionally reported, particularly at onset or at higher doses: enhanced colour saturation, visual sharpness, and sometimes olfactory clarity. These effects have been described as making the world feel 'more vivid' or 'more present.' Not universal; possibly related to NMDA modulation effects on sensory gating.
Non-response is a genuinely common outcome and should be treated as such. Experienced nootropic users who find no perceptible benefit are reporting honestly. Common explanations include product quality, individual pharmacokinetics, and the possibility that the compound's benefits require a specific cognitive deficiency to be apparent — users who are already cognitively well-optimised may have less headroom for improvement.
Community Consensus
Community discourse around Noopept is polarised more sharply than for most nootropics. A vocal subset reports significant life-improving effects — mood normalisation, study enhancement, verbal clarity, sensory sharpening.
A comparably sized group reports no perceptible acute effect at standard doses. Both positions are grounded in real experience and not easily dismissed; the polarisation likely reflects genuine phenotypic variability, product-quality differences, and the specific cognitive bottleneck the compound addresses.
The '1,000× more potent than piracetam' claim is the most consistently misunderstood piece of information in Noopept discourse. Community members frequently interpret this as meaning Noopept is 1,000× more effective at improving cognition, which is not what the comparison states. The 1,000× figure is a dose-weight equivalence: Noopept produces equivalent pharmacological activity at 1,000× lower doses by weight. Head-to-head human efficacy comparisons with piracetam do not exist.
The online Noopept landscape has been explicitly described as replete with misinformation, with users often sufficiently attached to their nootropic of choice to exaggerate benefits or downplay negatives. This makes independent source-critical synthesis more important for Noopept than for many compounds.
The regulatory grey-area status in Western markets is universally attributed to the absence of large-scale placebo-controlled English-language trials — a gap in evidence, not a safety signal. The Russian pharmaceutical evidence base supports therapeutic use in cognitive impairment populations but does not meet Western regulatory standards for approval.
Noopept is not classified as a peptide by practitioners who distinguish compounds by mechanism and structure. It is a small molecule with peptide heritage, grouped with neuropeptides in the nootropic community for historical and practical reasons rather than strict chemical classification.
Research-market quality is a significant confounder for all community experience data. Pharmaceutical-grade product shows more consistent reported outcomes than raw powder, where purity variation is substantial. Non-response and adverse reactions are both more common when product quality is uncertain.
Risks & Monitoring
Headache is the most common adverse effect, occurring in an estimated 20–30% of users in community aggregate data.
The mechanism is choline depletion: Noopept increases alpha-7 nicotinic acetylcholine receptor sensitivity and drives acetylcholine demand; when dietary or supplemental choline is insufficient, the resulting headache is characteristic. Choline support is the common response once headache appears.
Irritability and mood dysregulation are reported in approximately 10% of users by community aggregate estimates, with an 'afternoon irritability' pattern common in twice-daily dosing schedules. This appears to reflect stimulatory properties creating mood instability at certain dose intervals. Management is usually morning-only timing or dose reduction.
Sleep disruption is consistently reported with evening or late-afternoon dosing. The NMDA/AMPA modulation and activating properties remain active for hours after dosing. Morning/early-day timing is the most universally agreed-upon protocol rule across community sources.
Blood pressure elevation has been estimated at approximately 23% of users in a single community aggregate source, though this figure carries high uncertainty. One high-dose self-experiment with repeated BP monitoring did not show a BP rise, suggesting the BP signal may be idiosyncratic or dose-context-dependent.
Brain fog during initial use has been noted, typically resolving within the first days and possibly representing an adaptation phase. Occasional GI disturbance has been reported in susceptible users. Emotional sensitivity reduction — a dampening of emotional reactivity rather than the typical anxiolytic calm — is reported by a small subset of users and appears reversible on discontinuation. Tolerance develops with daily use and is the primary reason for cycling protocols; no evidence of physical or psychological dependence has been reported.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
A community aggregate estimate suggests up to 23% of users may experience BP elevation. Users with pre-existing hypertension or cardiovascular concerns should establish a baseline and monitor periodically, especially during the first cycle and at higher doses.
No known hepatotoxicity or nephrotoxicity at standard doses. CMP baseline is reasonable for users planning extended cycles or stacking with multiple compounds. Not required for short cycles in healthy adults.
Avoid With
Do not combine Noopept with the following. Sorted highest-severity first.
Why:Additive cholinergic demand. Noopept + racetams + high-dose choline can push acetylcholine tone beyond optimal, producing over-cholinergic headache, brain fog, or cognitive slowing.
What to do:Titrate choline supplementation rather than assuming more is better when stacking with other cholinergic nootropics.
Why:Noopept's NMDA/AMPA modulation and activating properties remain pharmacologically active for hours. Evening doses consistently disrupt sleep architecture and cause afternoon/evening irritability.
What to do:Not a stacking conflict — a timing rule. Front-load the day; no doses after approximately 2–3 pm.
Why:Noopept modulates NMDA receptors; combining with NMDA antagonists may produce unpredictable net effects on excitatory tone. No direct human data in the nootropic-use context.
What to do:Primarily relevant in clinical or therapeutic contexts rather than typical nootropic community use.
Protocols By Goal
For acute study-session enhancement — the most consistent and widely reported use case — take 10–20 mg oral or sublingual approximately 30–60 minutes before the session, alongside CDP-choline 200 mg or Alpha-GPC 150 mg.
Caffeine at a maintenance dose can be added. This protocol is most effective for dense technical reading, comprehension of complex material, and communication tasks requiring verbal clarity. The information retention and comprehension-speed effects are most reliably reported in this use context.
For verbal fluency specifically — the ability to articulate clearly in real-time — add CDP-choline 30–80 mg and uridine 100–300 mg to support the cholinergic fuel pathway. This stack is mechanistically coherent: Noopept creates cholinergic demand, CDP-choline provides choline substrate, and uridine supports CDP-choline synthesis via the membrane phospholipid pathway.
For neuroplasticity and long-term neurogenesis goals, Noopept pairs with dihexa and uridine at standard doses over a 4–6 week cycle. The compounds address different cognitive mechanisms: Noopept operates at the AMPA/cholinergic/HIF-1α level (information absorption); dihexa operates via the HGF/MET genomic pathway (recollection and stimulatory effects); uridine supports membrane synthesis and the CDP-choline pathway. These are additive, not redundant, and not interchangeable — users who substitute one for another expecting equivalent effects will be disappointed.
For neuroprotective use post-injury or in recovery contexts, the Russian clinical evidence supports 10 mg twice daily at the pharmaceutical prescribing standard, potentially stacked with Cerebrolysin (injectable) for a broader neurotrophic factor profile.
Dosing Details
Standard oral community dosing is typically described as 10–30 mg total daily, usually earlier in the day.
The Russian pharmaceutical prescribing standard is 10 mg twice daily after meals, but that clinical context is impaired-population treatment, not proof of healthy-adult enhancement.
The single most important reported protocol rule is to front-load the day. Evening and late-afternoon dosing consistently causes sleep disruption and afternoon/evening irritability across community reports.
Intranasal administration is discussed as a lower-dose, higher-bioavailability route, but it adds formulation and preservative risk. This article should not provide DIY spray preparation steps.
Sublingual use is reported as faster-onset than oral capsules because it partially bypasses first-pass metabolism.
Choline cofactor is mechanistically relevant. CDP-choline or Alpha-GPC are commonly paired when headache appears or when users are trying to protect the verbal-fluency/memory signal. Acetylcholine is the fuel pathway for Noopept's verbal fluency and memory effects.
The conservative community approach is to establish individual response at the lowest practical oral dose before splitting doses or escalating. The most common protocol mistake is starting too high or changing timing before establishing response.
Cycling is used to limit tolerance. Daily use can lose effect within weeks; occasional acute use for study sessions or presentations is often preferred over daily supplementation.
Stacks & Alternatives
Mechanistically required choline cofactor. Noopept increases alpha-7 nicotinic acetylcholine receptor sensitivity and acetylcholine demand; insufficient choline substrate causes characteristic headache. 200–300 mg per Noopept dose. This is not optional if headache is present.
Alternative choline cofactor to CDP-choline. Alpha-GPC 150–300 mg per Noopept dose. Slightly faster bioavailability than CDP-choline. Same mechanistic role — choline substrate for cholinergic demand.
Functional complement with a distinct mechanism: Noopept operates at the receptor level (information absorption); dihexa operates via HGF/MET genomic pathway (recollection, stimulatory effects). Additive, not redundant. NOT interchangeable — do not substitute one for the other expecting equivalent effects.
Nucleotide precursor supporting CDP-choline synthesis and neuronal membrane phospholipid pathway. 100–300 mg; reinforces the cholinergic fuel pathway Noopept depends on for verbal fluency and memory effects. Core component of the neuroplasticity stack.
Anxiolytic adjunct at higher Noopept doses. 100 mg L-Theanine is used to smooth activating effects at doses of 100 mg+ and support sleep when the evening cutoff rule is not possible. Standard anxiolytic pairing in community high-dose protocols.
Russian neuropeptide peer with complementary NGF/BDNF upregulation via a different receptor pathway (MC2R/MC4R signalling vs Noopept's HIF-1α/AMPA path). Semax is intranasal; Noopept is oral in this combination. Used in neuroprotection and mood stacks.
Injectable multi-factor neurotrophic protein hydrolysate. Both compounds are in the non-genomic neuropeptide functional tier. Cerebrolysin provides a broader neurotrophic cocktail; Noopept provides targeted oral CPG delivery. Used in recovery and neuroplasticity stacks where the user is already committed to injection protocols.
Alternatives
Stack Cost
Low-to-moderate stack tax: Noopept is oral, non-hormonal, non-suppressive, and cheap per dose, but it still consumes a cholinergic/timing lane and is unusually sensitive to source quality, sleep timing, and non-response.
The article repeatedly frames Noopept as an active AMPA/NMDA/cholinergic modulator rather than a neutral supplement. The same effects that support verbal fluency and information retention can produce headache, irritability, emotional flattening, brain fog, or sleep disruption when dose, choline, or timing are wrong.
Routine lab burden is light. The practical monitoring load is blood pressure in higher-risk users, sleep timing, headache/choline response, mood tone, and whether the user actually gets a measurable cognitive benefit.
The main conflict lane is additive cholinergic or excitatory nootropic stacking. Noopept plus racetams, high-dose choline, stimulants, or NMDA-active drugs can make attribution and dose-finding messy even when the absolute medical risk is not high.
Dose cost is low, but practicalitiesSummary and communityContext make product quality a major confounder. Research-market raw powder can turn a straightforward 10-20 mg trial into a purity, potency, or non-response problem.
- ·Counts as a cholinergic lane; do not stack aggressively with racetams, high-dose CDP-choline, high-dose Alpha-GPC, or other cholinergic nootropics before finding the minimum effective Noopept dose.
- ·Counts as a sleep-timing lane; morning and early-afternoon dosing are part of the protocol, not a preference.
- ·Does not consume an androgen, HPTA-suppression, GH/IGF, glucose, liver-toxic, or injection-logistics lane at standard oral doses.
- ·Treat response tracking as a capacity rule: if verbal fluency, comprehension, or memory encoding do not move after a clean trial with tested product, escalation is less attractive than stopping.
- ·For intranasal use, count formulation and preservative choice as an added logistics lane even though the compound itself remains non-hormonal.
- ·Choline cofactor plan: CDP-choline or Alpha-GPC only as needed and titrated to headache/cognition rather than pushed indefinitely upward.
- ·Morning-only dosing discipline with a hard late-afternoon cutoff.
- ·Cycle calendar or intermittent use plan to avoid tolerance from daily dosing.
- ·Blood-pressure baseline and periodic checks for users with hypertension, cardiovascular risk, stimulant stacks, or high-dose experimentation.
- ·Product-quality workflow for research-market powder or nasal preparations: identity/purity review, dose accuracy, and preservative choice.
Noopept is more beginner-compatible than hormonal, injectable, or organ-taxing compounds because it is oral, non-suppressive, and usually reversible. The caution is that a good trial still requires identity verification, conservative dose finding, choline judgment, morning-only timing, and acceptance that non-response is common.
- ·Uncontrolled hypertension or stimulant-heavy stack without blood-pressure tracking.
- ·History of severe insomnia, agitation, or medication-sensitive mood instability.
- ·Already using several racetams, cholinergics, or NMDA-active compounds and unable to isolate variables.
- ·Planning high-dose or intranasal experimentation before proving oral response.
Noopept has no hormonal suppression, no PCT requirement, and no described dependence signal. Most off-ramp issues are return-to-baseline cognition or mood, temporary loss of perceived study benefit, or sorting out whether headache/sleep/mood changes were Noopept, choline, stimulant use, or poor product quality.
- ·Return of the original study, verbal-fluency, or mood bottleneck.
- ·Short washout period needed to determine whether headache, irritability, or sleep disruption was compound-related.
- ·Loss of acute productivity benefit if the user was relying on Noopept for study sessions.
- ·Need to reassess source quality before any rechallenge after a failed trial.
Start low, keep choline available, and titrate cofactor support to response rather than treating high-dose choline as automatically protective.
Move dosing to morning-only or stop the second dose. The article's 2-3 pm cutoff is a core protocol rule.
Use identity/purity-documented product or pharmaceutical-grade product where available before concluding that the compound itself is ineffective.
Run Noopept alone or with one choline option first, then add complementary compounds only after a stable response is established.
The blood-pressure signal is uncertain, but the article still flags BP monitoring as prudent for users with baseline risk or stimulant-heavy stacks.
Headache is the main dose-limiting event and usually points to a cholinergic mismatch; persistence after correction means the trial is not clean.
The article describes sleep disruption, irritability, and emotional sensitivity reduction as reversible but meaningful stop signals.
womenConsiderations notes no reproductive safety data. The absence of known HPG-axis effects is not evidence of pregnancy or lactation safety.
Practical Setup
Choline supplementation becomes important once headache occurs. CDP-choline or Alpha-GPC are commonly used as the cofactor response because the choline requirement is mechanistically tied to Noopept's cholinergic effects, not just an idiosyncratic reaction.
A conservative community pattern is to establish response with a single morning oral dose before adding a second dose. The most commonly cited protocol mistake is starting too high or splitting doses before establishing individual response.
Product quality is the single largest confounder in community experience data. A nominal dose from uncertain raw powder may contain substantially more or less active compound than stated. Third-party testing and pharmaceutical-grade products reduce that uncertainty.
For users with GI sensitivity, intranasal administration is discussed because it bypasses the GI tract, but it adds formulation and preservative risks. DIY nasal-spray preparation should not be treated as a casual reader-facing protocol.
Timing is the most impactful protocol variable. Morning and early afternoon use dominates community reports because late dosing is the clearest sleep-disruption pattern.
Cycling is used to prevent tolerance. Occasional acute use for study sessions or presentations may avoid tolerance better than daily supplementation.
The Western regulatory grey-area status reflects an evidence gap — the absence of large-scale placebo-controlled English-language trials — not a safety finding. The Russian pharmaceutical evidence base supports therapeutic use for specific impaired populations; community use in healthy adults is outside the scope of that evidence.
Emotional blunting is a possible adverse effect in a small subset of users — dampened emotional reactivity rather than the anxiolytic calm most users experience. This appears reversible on discontinuation. Reduce dose or discontinue if unwanted emotional flattening is noticed.
Mechanism Deep Dive
Noopept does not appear in blood samples after oral administration. Instead, it is hydrolyzed — at or after crossing the blood-brain barrier — to its active metabolite cycloprolylglycine (CPG), a naturally occurring dipeptide consisting of proline and glycine. CPG is the pharmacologically active species responsible for Noopept's cognitive effects. This prodrug mechanism is why standard drug screening does not detect Noopept after oral dosing, and why its effects are characterised by a delay and a dose-response that differs from immediate-release stimulants.
CPG modulates AMPA and NMDA receptor function. AMPA receptor potentiation enhances fast excitatory synaptic transmission and is mechanistically linked to improved memory encoding and information retention. NMDA receptor modulation supports long-term potentiation while simultaneously providing protection against glutamate excitotoxicity — the compound's neuroprotective and cognitive-enhancement roles operate through the same receptor targets but in different directions depending on the stimulus context.
Noopept also enhances alpha-7 nicotinic acetylcholine receptor (α7nAChR) sensitivity, increasing cholinosensitivity and explaining the observed synergy with choline supplementation, the verbal fluency effect, and the dose-limiting headache that develops when acetylcholine demand exceeds supply. Acetylcholine is the functional fuel pathway for the verbal fluency and memory encoding effects.
At the transcriptional level, acute administration increases mRNA expression of both NGF (nerve growth factor) and BDNF (brain-derived neurotrophic factor) in the hippocampus — regions definitively associated with memory consolidation. The widely circulated '43% BDNF increase' figure originates from rodent studies and should not be extrapolated to human outcomes; no human BDNF quantification exists. After 28 days of chronic dosing, BDNF mRNA upregulation extends to the hypothalamus — a broader distribution that may underlie the mood-stabilising and anxiolytic effects seen with longer-term use.
Noopept also activates HIF-1α (hypoxia-inducible factor 1-alpha) by inhibiting PHD2 (prolyl hydroxylase domain protein 2), providing neuroprotective effects under hypoxic or ischaemic conditions. This mechanism is the basis for its Russian pharmaceutical indication in post-stroke and TBI-related cognitive impairment. At the EEG level, Noopept and piracetam produce similar patterns in conscious rats — the mechanistic basis for their functional grouping despite structural differences.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Noopept is roughly 1,000 times more potent by weight than piracetam
Dose-equivalence comparison only, not an efficacy claim. No human head-to-head efficacy trial exists. The comparison means Noopept achieves equivalent pharmacological activity at 1,000× lower doses by weight — not that it produces 1,000× greater cognitive improvement.
Acute Noopept administration increased mRNA expression of both NGF and BDNF in the rat hippocampus; chronic 28-day dosing increased BDNF mRNA in both hippocampus and hypothalamus
Human neurotrophic factor data for Noopept are absent. The 43% BDNF figure cited in editorial sources derives from rodent data and should not be extrapolated to human outcomes.
A small Russian RCT demonstrated cognitive benefits of Noopept vs piracetam in patients with mild cognitive impairment
Active-controlled vs piracetam — not placebo-controlled. Russian-language publication, not in English peer-reviewed journals. Therapeutic indication population, not healthy adults. This is the only RCT in humans.
Headache occurs in approximately 20–30% of users
Order-of-magnitude community aggregate estimate from a single editorial source. High uncertainty — not a clinical incidence figure. Mechanistically plausible (choline depletion).
Blood pressure elevation occurs in approximately 23% of users
Single editorial source synthesising community data. Contradicted by a stable-BP high-dose self-experiment. Treat as highly uncertain.
Russian pharmaceutical prescribing: 10 mg twice daily after meals
Therapeutic indication population. Community use in healthy adults follows a similar dose range but the indication and population differ substantially.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.